SCA
IMCR icon

Snowden Capital Advisors’s Immunocore IMCR Stock Holding History

Snowden Capital Advisors’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,430
Closed -$224K – 1370
2026
Q1 		$224K Buy
7,430
+460
+7% +$14.9K 0.01% 1164
2025
Q4 		$242K Sell
6,970
-578
-8% -$20.4K 0.01% 1137
2025
Q3 		$274K Sell
7,548
-126
-2% -$4.28K 0.01% 1055
2025
Q2 		$241K Buy
7,674
+198
+3% +$6.15K 0.01% 1100
2025
Q1 		$222K Sell
7,476
-197
-3% -$5.91K 0.01% 1118
2024
Q4 		$226K Sell
7,673
-138
-2% -$4.36K 0.01% 1110
2024
Q3 		$243K Buy
7,811
+179
+2% +$6.51K 0.01% 1105
2024
Q2 		$259K Buy
7,632
+137
+2% +$6.99K 0.01% 1027
2024
Q1 		$487K Sell
7,495
-42
-0.6% -$2.88K 0.02% 774
2023
Q4 		$515K Buy
7,537
+289
+4% +$15K 0.02% 682
2023
Q3 		$376K Buy
7,248
+1,729
+31% +$102K 0.02% 775
2023
Q2 		$331K Buy
+5,519
New +$315K 0.01% 918

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Snowden Capital Advisors's IMCR Position: Q2 2026 in Review

Snowden Capital Advisors sold out of Immunocore (IMCR) in Q2 2026, closing a stake of 7,430 shares — an estimated $224K sold.

Snowden Capital Advisors first reported a position in IMCR in Q2 2023 and held it in 12 quarters. The position peaked at $515K in Q4 2023. 135 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Snowden Capital Advisors reported no remaining Immunocore position as of Q2 2026 after selling out during the quarter.
  • Snowden Capital Advisors sold 7,430 Immunocore shares in Q2 2026, an estimated $224K.
  • Snowden Capital Advisors first reported a position in Immunocore in Q2 2023 and held it in 12 quarters.
  • Snowden Capital Advisors's Immunocore position peaked at $515K in Q4 2023.
  • 135 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.